OncoMatch/Clinical Trials/NCT06178601
A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma
Is NCT06178601 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including RC48-ADC and AK104 for urothelial carcinoma.
Treatment: RC48-ADC · AK104 — This study will evaluate the efficacy and safety of RC48-ADC combined with AK104 in HER2-expression locally advanced or metastatic urothelial carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (IHC 1+, 2+, or 3+)
HER2 expressing (i.e. IHC 1+ 2+ or 3+) as confirmed by the local lab
Disease stage
Metastatic disease required
locally advanced or metastatic urothelial carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antitumor therapy
Has received other antitumor therapy before planned start of trial treatment
Lab requirements
Blood counts
Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment
Kidney function
Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment
Liver function
Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment
Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify